Larifan

Larifan is a winner for several strong reasons:

Unique dsRNA Technology: Larifan is based on a patented, naturally derived double-stranded RNA that acts as a powerful inducer of the body’s innate immune response by stimulating endogenous interferon production. No other registered drug on the EU or UK market offers this combination of immunomodulatory, antiviral, and anticancer properties.

Proven Clinical and Preclinical Data: Larifan has demonstrated efficacy and safety in multiple clinical trials and experimental studies spanning viral infections including COVID-19, herpes, influenza, and tick-borne encephalitis, as well as immunodeficiencies and tumor models.

Broad Spectrum Antiviral Activity: Unlike many antiviral drugs that target single viruses, Larifan works across a wide spectrum of RNA and DNA viruses, offering broad protection and treatment capabilities.

Registered and Commercialized: Larifan is already approved and commercially available in multiple EU countries and parts of Asia, establishing market validation, operational capability, and sales traction.

Scalable Production and Regulatory Pathway: The product is manufactured under GMP conditions and is undergoing regulatory approval for MHRA in the UK, facilitating entry into one of the world’s leading healthcare markets.

Strong IP Portfolio: Comprehensive patents protect the formulation, production, and therapeutic uses of Larifan, providing a competitive moat.

Market Demand: With rising global viral infections and immunodeficiency issues, there is a growing unmet need for innovative, safe, and effective immunomodulatory antivirals.

Together, these factors position Larifan as a unique and scalable healthcare solution, addressing urgent medical needs with a strong path to growth and market expansion. This makes it highly attractive for investors seeking transformative, evidence-backed biotech innovations.

Our current and intended business/revenue model for Larifan is primarily based on the commercialization of the product through regulated pharmaceutical channels. Key components include:

Direct sales of Larifan drug formulations to hospitals, clinics, and healthcare providers in regions where it is registered (currently EU, parts of Asia, and soon UK after MHRA approval).

Licensing and partnership agreements with pharmaceutical companies and contract manufacturing organizations (CDMOs) to scale production and distribution.

Potential expansion into consumer health and over-the-counter (OTC) immunomodulatory and antiviral supplements and sprays, leveraging Larifan’s natural and safe profile.

Participation in public and private healthcare tenders, insurance reimbursement programs, and national health formularies to ensure wide clinical adoption and sustained revenue streams.

Continued investment in clinical research and development to expand indications and increase market penetration.

This model ensures multiple revenue streams from prescription pharmaceuticals, strategic partnerships, and possibly OTC products, aligned with current market demand and regulatory frameworks.

The model aims for sustainable growth via geographic expansion and broadening therapeutic indications, maximizing Larifan’s potential as an innovative immunomodulatory and antiviral agent.

Yes, we have registered patents and IP related to Larifan and its technology. The core innovation lies in the unique double-stranded RNA (dsRNA) structure derived from bacteriophages infecting Escherichia coli, which acts as a natural inducer of endogenous interferon production.

Our patents cover the production method, formulation, and therapeutic uses of Larifan in antiviral and immunomodulatory treatments. These patents have been registered in major markets including the EU, parts of Asia, and are part of our strategy for MHRA approval and UK market entry.
The scientific uniqueness and protected intellectual property form a strong competitive advantage and are integral to our investment proposal.
METHOD FOR PRODUCTION OF INTERFERON INDUCER DOUBLE HELIX RNA

LV14897A; LV14897B

Larifan technology is already implemented in several fields and sectors:

Medical and healthcare sector — it is used clinically as an antiviral and immunomodulatory agent for prevention and treatment of viral infections such as herpes, influenza, tick-borne encephalitis, COVID-19, and others.

Oncology — Larifan demonstrated antitumor and antimetastatic properties in preclinical studies, showing promise as adjunct immunotherapy.

Public health and epidemic control — due to broad-spectrum antiviral activity, it has applications in addressing viral outbreaks and reducing disease burden.

Registered and marketed in parts of the EU and Asia, with a commercial presence and ongoing regulatory approval efforts in other markets such as the UK.

Implementation includes clinical use in hospitals, outpatient care, and inclusion in national pharmacopeia's in countries where it is registered.

If you want, I can provide detailed data on real-world applications and clinical usage documented in official reports and scientific publications.

The products Larifan is targeting solve several critical market and customer needs/problems in the antiviral and immunomodulatory therapy sectors:

Larifan addresses the high unmet need for effective, broad-spectrum antiviral agents capable of combating a wide range of viral infections including herpesvirus, influenza, coronaviruses (including SARS-CoV-2), and others. Many existing antiviral treatments have limited efficacy or are virus-specific; Larifan's unique double-stranded RNA (dsRNA) mechanism induces endogenous interferon production, providing a potent, wide-ranging antiviral defense.

It also tackles immune dysregulation problems by acting as an immunomodulator. This can support patients with secondary immunodeficiency caused by infections or therapies (e.g., tumor therapy), where boosting the immune system safely is critical.

Additionally, Larifan has demonstrated antitumor and antimetastatic effects, addressing gaps in cancer immunotherapy by enhancing innate immunity and activating T cells and NK cells to combat cancer progression.

The product responds to the growing global demand for innovative biologics that can mitigate viral pandemics and reduce the burden of recurrent infections while offering a safer safety profile than synthetic drugs or direct interferon administration.

Larifan's current market focus includes EU and Asia with plans for MHRA approval in the UK, targeting healthcare systems and patients needing reliable, regulatory-approved immune therapies that are effective both prophylactically and therapeutically.

Thus, Larifan aims to solve the dual problems of insufficient broad-spectrum antiviral agents and unmet needs in immune system modulation, providing a novel, scientifically validated approach with significant global market potential.

This aligns well with trends showing a global antiviral drugs market size estimated at approximately USD 67 billion in 2025, expected to grow steadily over the next decade, driven by increasing viral disease prevalence and demand for innovative therapies.